Keywords: GlaxoSmithKline, Dabrafenib, Trametinib, BRAF positive melanoma, Ph III

GlaxoSmithKline initiates Ph III study to test dabrafenib and trametinib combo for BRAF positive melanoma

Article | 04 February 2013

Print This

UK pharma giant GlaxoSmithKline (LSE: GSK) has initiated COMBI-AD, a Phase III study evaluating the combination of dabrafenib, its BRAF ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in